ESR1 and breast cancer: Also the selective ER degrader Fulvestrant has an important role in breast cancer treatment (Nathan and Schmid, 2017) and a number of additional novel therapeutic compounds with improved pharmacokinetics act at the receptor level and are under investigation (Furman et al., 2019).